SynthesisCancer metastasis reviews2022
Adipocytokines and disease progression in endometrial cancer: a systematic review.
Synthesis in Cancer metastasis reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Tumor-metabolism integrated therapy: A new paradigm for fertility-sparing treatment in endometrial cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- GPX3 improves endometrial receptivity by inhibiting ferroptosis via the Nrf2/GPX4 signaling pathway in sows.Zoological research · 2026Article
- Laparoscopic vs. open surgery for early-stage endometrial cancer: effect on inflammatory factors and quality of life.American journal of translational research · 2026Article
- The Role of "Metabolic Instability" as a New Risk Criterion in the Pathogenesis of Endometrial Cancer.Cancers · 2025Review
- Exploring the Relationship Between Adipocytokines and Endometrial Cancer: Identifying Correlations With Clinico-Pathological Prognostic Factors.Cancer medicine · 2025Article
- Unravelling the Adiponectin Hallmark and Exploring the Therapeutic Potential of Its Receptor Agonists in Cancer Metabolic Reprogramming.Biomolecules · 2025Review
- Bidirectional crosstalk between sleep disorders and gynecological cancers: unraveling molecular synergies and precision therapeutics.Frontiers in medicine · 2025Review
- Causal relationship between inflammatory factors and gynecological cancer: a Bayesian Mendelian randomization study.Scientific reports · 2024Article
- Article
- The Impact of High Adiposity on Endometrial Progesterone Response and Metallothionein Regulation.The Journal of clinical endocrinology and metabolism · 2024Article
- Review
- Circulating Adipocytokines and Insulin Like-Growth Factors and Their Modulation in Obesity-Associated Endometrial Cancer.Cancers · 2024Article
- Review
- The role of neck adipose tissue in lymph node metastasis of head and neck cancer.Frontiers in oncology · 2024Review
- The role of ncRNAs and exosomes in the development and progression of endometrial cancer.Frontiers in oncology · 2024Review
- Review
- Update on Adipose Tissue and Cancer.Endocrine reviews · 2023Article
- The interplay of obesity, microbiome dynamics, and innovative anti-obesity strategies in the context of endometrial cancer progression and therapeutic approaches.Biochimica et biophysica acta. Reviews on cancer · 2023Review
- Review
- Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer.Journal of translational medicine · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the study was to document the effect of adipocytokines on endometrial cancer progression. A search of the databases CINAHL, Medline, PubMed, Cochrane, Web of Science, Embase and Google Scholar was performed for English language articles from January 2000 to December 2020 using the keywords: (Endometrial cancer) AND (progression OR metastasis) AND (adipocytokine OR adiponectin OR leptin OR visfatin OR IL-6 OR TNF-α OR adipokine OR cytokine). Forty-nine studies on adipocytokines have been included in this review. Adiponectin has been linked with anti-proliferative and anti-metastatic effects on endometrial cancer cells and is associated with a better prognosis. Leptin, visfatin and resistin are linked to the stimulation of endometrial cancer growth, proliferation, invasion and metastasis and are associated with worse prognosis or with a higher grade/stage of endometrial cancer. IL-6, Il-11, IL-31, IL-33, TNF-α, TGF-β1, SDF-1 and CXCR are involved in endometrial cancer cell growth and metastasis or involved in epithelial mesenchymal transformation (EMT) or associated with advanced disease. Adipocytokines have been found to directly impact endometrial cancer cell proliferation, invasion and migration. These molecules and their signalling pathways may be used to determine prognosis and course of the disease and may also be exploited as potential targets for cancer treatment and prevention of progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.